Year Founded
2018
Ownership
Private
Employees
~50
Stage
Other
Modalities
Medical devicesSmall molecule

Intrance Medical Systems General Information

Developing a fixed-dose combination of carbidopa + entacapone + levodopa for enteral infusion in advanced Parkinson's disease patients. Product is already commercialized in Europe as Lecigon.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
New York, New York
United States

Drug Pipeline

carbidopa + entacapone + levodopa
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Intrance Medical Systems's pipeline data

Book a demo

Key Partnerships

STADA/Britannia

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Intrance Medical Systems Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Intrance Medical Systems's complete valuation and funding history, request access »

Intrance Medical Systems Investors

Erik Selin (through Erik Selin Fastigheter AB)
Investor Type: Venture Capital
Holding: Minority
Rutger Arnhult
Investor Type: Venture Capital
Holding: Minority
Lobsor Pharmaceuticals
Investor Type: Venture Capital
Holding: Minority